Key Companies in the Bile Duct Cancer Market

Why Is Bile Duct Cancer Treatment Expanding?

Two structural catalysts anchor this trajectory: the rising global incidence of cholangiocarcinoma, which now accounts for approximately 3% of all gastrointestinal malignancies and 15--25% of primary liver cancers, and a wave of targeted therapy approvals that have transformed the treatment paradigm from cytotoxic chemotherapy to precision oncology. The FDA's 2020 approval of pemigatinib (Pemazyre) for FGFR2 fusion-positive intrahepatic cholangiocarcinoma marked the first targeted therapy for this indication, followed by ivosidenib (Tibsovo) for IDH1-mutated disease and futibatinib (Lytgobi) for FGFR2-rearranged tumors --- a regulatory momentum that has redirected significant R&D investment toward molecularly stratified cholangiocarcinoma pipelines.

The clinical approach to bile duct cancer is undergoing a fundamental change. Targeted Therapy holds almost 42% of 2025 market revenue, while Immunotherapy is the fastest-growing segment, driven by checkpoint inhibitor combos in first-line settings. First-Line Therapy dominates the therapeutic setting with around a 55% share. North America accounts for about 38% of global revenue, while Asia-Pacific is the fastest-growing region.

What Structurally Separates Leaders from the Field?

MRFR identifies four structural factors that define category leadership: proprietary biomarker-driven drug platforms with validated companion diagnostics; regulatory dossier depth spanning accelerated approval, breakthrough therapy designation, and post-marketing confirmatory trial commitments; clinical evidence generation through sponsor-initiated randomized trials; and global commercial infrastructure with specialized oncology sales forces.

Top 10 Global Bile Duct Cancer Companies --- MRFR Rankings (2026)

MRFR has identified and profiled the following leading bile duct cancer treatment companies globally. Figures below have been validated against company filings, investor-relations disclosures, and official company websites as of July 2026. Items marked with an asterisk (*) could not be independently verified from public filings and are retained as company- or analyst-reported estimates. Items marked with a dagger (†) indicate corrections to the original report.

Detailed Company Profiles

1. Merck & Co. (MSD) | NYSE: MRK | Rahway, New Jersey, USA

Merck & Co. reported total sales of USD 65.011 billion in FY2025, per its SEC Form 10-K filing, with Keytruda (pembrolizumab) generating USD 31.641 billion in global sales (not USD 29.5 billion as stated in the original report). The company's strategic position in bile duct cancer is anchored in Keytruda, the world's best-selling oncology drug. 

2. Roche / Genentech | SIX: ROG / OTCQX: RHHBY | Basel, Switzerland

Roche’s Annual Report shows group sales of CHF 61.516 billion in FY2025, of which Pharmaceuticals generated CHF 47.669 billion and Diagnostics CHF 13.847 billion. Roche’s integrated pharma-diagnostics model is its strategic differentiator, with Roche developing Tecentriq (atezolizumab) but also commercialising FoundationOne CDx comprehensive genomic profiling. The Tecentriq + Avastin combination was recognized as a standard of care in liver malignancies, thanks to Roche’s IMbrave150 trial in hepatocellular carcinoma. The company's 100+ country footprint and installed base of diagnostics gives it a unique competitive positioning.

3. AstraZeneca | Nasdaq: AZN | Cambridge, United Kingdom

AstraZeneca’s SEC Form 20-F filing showed total revenue of USD 58.739 billion for FY2025, of which the Oncology segment generated USD 25.619 billion (not USD 23.1 billion as stated in the original report) --- the company’s largest and fastest-growing therapeutic area, up 15% (14% CER) year-over-year. The company’s strategy for bile duct cancer is based on two pillars — Imfinzi (durvalumab), which was approved in combination with chemotherapy for biliary tract cancer based on the TOPAZ-1 trial (approved September 2, 2022), and Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate. AstraZeneca’s commercial infrastructure in 100+ countries focused on oncology provides the density to drive rapid adoption.

4. Pfizer | NYSE: PFE | New York, New York, USA

Pfizer reported total revenues of USD 62.6 billion in FY2025, per its SEC Form 10-K filing. The company's strategic position in bile duct cancer is anchored in its targeted therapy and immunotherapy portfolio. Pfizer's December 2023 acquisition of Seagen for approximately USD 43 billion (net of cash; USD 44 billion total fair value) added a leading ADC platform including Padcev (enfortumab vedotin) and Adcetris (brentuximab vedotin). The company's 185+ country presence and manufacturing scale provide supply chain resilience.

5. Bristol-Myers Squibb | NYSE: BMY | Princeton, New Jersey, USA

Bristol-Myers Squibb recorded total revenues of USD 48.194 billion in FY2025, according to its SEC Form 10-K filing. Note: The original story wrongly mentioned FY2024 revenue of USD 48.3 billion and a 2025 projection of ~USD 45.5 billion. FY2025 revenue was USD 48.194 billion. FY2026 projection is USD 46.0--47.5 billion. The company’s strategic position in bile duct cancer is based on Opdivo (nivolumab) and Yervoy (ipilimumab). U.S. Approval of Opdivo Qvantig (Subcutaneous Nivolumab): BMS received U.S. The Company’s Growth Portfolio contributed USD 22.6 billion for FY2024, up 17% year-over-year.

6. Bayer AG | XETRA: BAYN | Leverkusen, Germany

Bayer AG is a German multinational pharmaceutical and biotechnology business with headquarters in Leverkusen, Germany. As of the date of this research (July 2026), the claimed EUR 45.6 billion total revenue and EUR 18.2 billion Pharma segment revenue for FY2025 could not be independently verified via official Bayer annual report filings. Wikipedia has Bayer’s 2024 revenue at EUR 46.6 billion. Stivarga (regorafenib) is a multi-kinase inhibitor approved for hepatocellular carcinoma and gastrointestinal stromal tumors, and is being studied in combination regimens for cholangiocarcinoma. Stivarga is the centerpiece of the company’s strategic position in bile duct cancer.

7. Incyte Corporation | Nasdaq: INCY | Wilmington, Delaware, USA

Incyte Corporation reported total revenue of USD 5.14 billion in FY2025, per its SEC Form 10-K filing. Note: The exact Jakafi (ruxolitinib) revenue figure of ~USD 2.6 billion cited in the original report could not be independently verified from the FY2025 10-K segment breakdown as of July 2026. Incyte's strategic moat in bile duct cancer is built on Pemazyre --- the first FDA-approved FGFR inhibitor for cholangiocarcinoma, approved in April 2020 (not May 2020 as stated in the original report) for FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma based on the FIGHT-202 trial. The company's FGFR franchise includes next-generation FGFR inhibitors designed to address resistance mutations.

8. Eisai Co. | TSE: 4523 / OTC: ESALY | Tokyo, Japan

Eisai Co. reported total revenue of JPY 825.4 billion (~USD 5.39 billion) in FY2025, per its Annual Report and earnings disclosures. The company's strategic position in bile duct cancer is anchored in Lenvima (lenvatinib), a multi-kinase inhibitor approved for hepatocellular carcinoma and thyroid cancer, with clinical trials ongoing in biliary tract malignancies --- particularly in combination with Keytruda. Eisai's deep relationships with Japanese hepatobiliary surgeons provide a captive demand pipeline for Lenvima in biliary tract malignancies.

9. Servier | Private | Suresnes, France

Servier reported total revenue of EUR 6.86 billion in FY2024/25, per its Annual Report, making it one of the largest privately held pharmaceutical companies globally. The company's strategic position in bile duct cancer is anchored in Tibsovo (ivosidenib), an IDH1 inhibitor approved by the FDA on August 25, 2021, for previously treated IDH1-mutated cholangiocarcinoma based on the Phase III ClarIDHy trial. Servier acquired Tibsovo through its partnership with Agios Pharmaceuticals and subsequent acquisition of Agios' oncology portfolio. Note: The original report stated the Servier/Agios deal value as USD 2.0 billion. Per SEC filings, the actual transaction was USD 1.8 billion upfront plus a USD 200 million regulatory milestone and royalty payments on U.S. net sales of Tibsovo and vorasidenib.

10. Taiho Pharmaceutical (Otsuka Group) | Subsidiary of Otsuka Holdings | Tokyo, Japan

Taiho Pharmaceutical reported non-consolidated sales of JPY 215.6 billion (~USD 1.4 billion) in FY2025, per its corporate disclosures, and operates as a subsidiary of Otsuka Holdings, which reported total group revenue of JPY 2,468.9 billion (~USD 16.2 billion) in FY2025. Taiho's strategic position in gastrointestinal oncology is anchored in Lonsurf (trifluridine/tipiracil), approved for metastatic colorectal cancer and gastric cancer, with clinical exploration ongoing in biliary tract malignancies. Lonsurf is not yet approved for biliary tract cancer --- a gap that confines Taiho to clinical-trial and off-label segments.

M&A Activity Tracker (2019--2023)

The following transactions have been verified from named company press releases and SEC filings.

Key Trend (Analyst Assessment): Biomarker-driven diagnostic-drug integration is the dominant competitive dynamic. Roche's FoundationOne CDx + Tecentriq model, AstraZeneca's Enhertu + HER2 testing strategy, and Incyte's Pemazyre + FGFR2 fusion detection demonstrate a market pivot from empiric chemotherapy toward molecularly stratified therapy selection. By 2030, MRFR projects that biomarker-guided therapy will capture 65--70% of biliary tract cancer treatment decisions. These projections are proprietary MRFR estimates and have not been independently validated.

R&D Investment & Innovation Signals

• Merck’s Keytruda had $31.641 billion in FY2025 global sales (not $29.5 billion as stated in the original report). Keytruda was approved by the FDA for biliary tract cancer on October 31, 2023 (not September 2022) based on the KEYNOTE-966 trial. The original story wrongly lumped this along with AstraZeneca’s durvalumab (Imfinzi) TOPAZ-1 approval on September 2, 2022.

• Roche's Tecentriq + Avastin combination in the IMbrave150 trial demonstrated activity in liver malignancies, while FoundationOne CDx identifies FGFR2 fusions, IDH1 mutations, and MSI-H status. Roche reported CHF 61.516 billion in group sales for FY2025, with Pharma at CHF 47.669 billion.

• AstraZeneca's Oncology segment reached USD 25.619 billion in FY2025 (not USD 23.1 billion as stated in the original report), growing 15% (14% CER). Imfinzi generated USD 6.063 billion. Enhertu demonstrated activity in HER2-positive biliary tract malignancies through the DESTINY-PanTumor02 basket trial.

• Pfizer's USD 43 billion acquisition of Seagen in December 2023 (net of cash; USD 44 billion total fair value) added Padcev and Adcetris to its ADC portfolio. Pfizer reported total revenues of USD 62.6 billion in FY2025.

• Bristol-Myers Squibb's Opdivo Qvantig (subcutaneous nivolumab) received U.S. approval in 2025. BMS reported FY2025 total revenues of USD 48.194 billion (not FY2024 USD 48.3 billion with 2025 guidance of USD 45.5 billion as incorrectly stated). FY2026 guidance is USD 46.0--47.5 billion.

• Incyte's Pemazyre remains the only FDA-approved FGFR inhibitor for cholangiocarcinoma, approved in April 2020 (not May 2020). The FIGHT-202 trial established a 35.5% objective response rate in FGFR2 fusion-positive patients. Incyte reported FY2025 total revenue of USD 5.14 billion.

• Servier's Tibsovo (ivosidenib) is the only approved IDH1 inhibitor for cholangiocarcinoma, approved August 25, 2021, based on the ClarIDHy trial. Servier acquired Agios' oncology portfolio for USD 1.8 billion upfront (not USD 2.0 billion as stated) plus milestones and royalties.

• By 2030, MRFR projects that biomarker-guided therapy will capture 65--70% of biliary tract cancer treatment decisions. This is a proprietary MRFR forecast and has not been independently validated.